Recent progress in the management of invasive fungal infections in hematopoietic stem cell transplant recipients

摘要

Invasive fungal infection (IFI) is a majornsource of morbidity and mortality innpatients following hematopoietic stemcellntransplantation (HSCT), especiallynin those who have prolonged periods ofnneutropenia and/or graft versus hostndisease (GVHD). Improved reportingnof the prevalence of infection is makingnclinicians more aware of the need to tailornantifungal therapy to local trends,nand recent national and internationalnguidelines have drawn attention to thenadvantages and disadvantages of differentntreatment strategies. As recommendationsnstart to be implemented, datanare emerging about the cost implicationsnof initiating antifungal therapy atnvarious stages following HSCT.nThis year’s annual meeting of thenEuropean Group for Blood and MarrownTransplantation (EBMT), in Florence,nItaly, proved a valuable forum forndiscussion of these new developmentsnand of the implications for routinenclinical practice.